Effects of PPARγ Ligands on Prostate and Bladder Cancer Cells
Author Information
Author(s): Christine L. Chaffer, David M. Thomas, Erik W. Thompson, Elizabeth D. Williams
Primary Institution: Bernard O'Brien Institute of Microsurgery, Victoria, Australia
Hypothesis
PPARγ ligands induce growth arrest and apoptosis in prostate and bladder carcinoma cell lines through PPARγ-independent mechanisms.
Conclusion
Troglitazone and 15-deoxy-prostaglandin J2 inhibit growth of prostate and bladder carcinoma cell lines through different mechanisms and the effects of both agents are PPARγ-independent.
Supporting Evidence
- Troglitazone and 15dPGJ2 significantly inhibited cell growth in prostate and bladder carcinoma cell lines.
- The effects of these ligands were not reversed by the PPARγ antagonist GW9662.
- Different PPARγ ligands induced distinct cellular responses, including growth arrest and apoptosis.
Takeaway
Some medicines can stop cancer cells from growing and even make them die, and they do this without using a specific target in the body.
Methodology
The study examined the effects of various PPARγ ligands on cell proliferation, growth arrest, and apoptosis in multiple prostate and bladder carcinoma cell lines using assays like FACS analysis and caspase activation.
Limitations
The study does not specify the long-term effects of the treatments or their efficacy in vivo.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website